Keyword: Moderna Therapeutics
Moderna has opted to enter a licensing deal with U.K.-based Avacta Group to use the U.K.-based company’s Affimer biotherapeutics and reagents.
After a year that saw biotech IPOs raise $6.3 billion and Moderna pull off a history-making $604 million listing, valuations may come down in 2019.
Moderna’s much-anticipated IPO has come in even larger than expected at $604 million, valuing the company at an eye-watering $7.9 billion.
Synthorx wants a $100 million IPO, but is the window closing?
Two months after rumblings emerged that Moderna Therapeutics was prepping what would be biotech’s biggest IPO, the company has come through.
Already cash-rich, Moderna Therapeutics is said to be planning an IPO to extend its resources even further and advance its mRNA-based drugs.
Sean Harper to help run $320M VC fund; Agios crowns Jackie Fouse as CEO; and hospital-backed Civica Rx nabs Amgen vet as CEO.
Pfizer has also committed to up to $305 million in development, regulatory and commercial milestones to seal the deal.
CAR-T maker Cell Medica names Kite’s European chief as CEO; Oncorus poaches a Moderna cancer executive; and Achaogen axes R&D and its C-suite.
Oncorus has nabbed Moderna’s head of oncology development, Theodore (Ted) T. Ashburn, M.D., Ph.D., as its new chief executive and president.